Electronic Supplementary Material (ESI) for Journal of Materials Chemistry B.
This journal is © The Royal Society of Chemistry 2014

**SUPPORTING INFORMATION**

# Self-Assembling Doxorubicin-Prodrug nanoparticles as siRNA Drug Delivery System for Cancer Treatment: *in vitro* and *in vivo*

Hongmei Liu,[ab] Chenmeng Qiao,[c] Jun Yang,[a] Jie Weng *[c] and Xin Zhang*[a]




**Fig. S1** High resolution mass spectroscopy to determine the exact mass and the corresponding molecular formula of the C18-N-DOX.




**Fig. S2** The fluorescence spectra of the DOX solution (water: DMSO = 8:2) (1.5 μM) with the increasing molar ratios of siRNA (from top to bottom: 0, 0.05, 0.15, 0.2 and 0.3 nmol).




**Fig. S3** The fluorescence spectra of the DOX-prodrug solution (water:DMSO = 8:2) (1.5 μM) with the increasing molar ratios of siRNA (from top to bottom: 0, 0.05, 0.15, 0.2 and 0.3 nmol).




**Fig. S4** The fluorescence spectra of the DOX-prodrug NPs solution (2 mg $mL^{-1}$) with the increasing molar of siRNA.



**Fig. S5** The Cryo-TEM images of DOX-prodrug NPs.




**Fig. S6** Release profiles of DOX from DOX-prodrug NPs (n = 3)




**Fig. S7** The UV-visible absorbance spectra of DOX and C18-N-DOX.




**Fig. S8** a) CLSM images of *HeLa* cells show the cellular uptake of DOX-prodrug NPs and DOX-prodrug NPs/siRNA (at equivalent DOX concentration of 2 μg $mL^{-1}$) for 2 h. b) DOX-released from DOX-prodrug NPs and DOX-prodrug NPs/siRNA (at equivalent DOX concentration of 2 μg $mL^{-1}$) for 24 h as measured using CLSM.